Mylan Institutional LLC’s June 25, 2026 FDA approval for intravenous ferric carboxymaltose is expected to introduce a generic alternative to the market, potentially reshaping the competitive dynamics of intravenous iron therapies.
Mylan Institutional LLC’s June 25, 2026 FDA approval for intravenous ferric carboxymaltose is expected to introduce a generic alternative to the market, potentially reshaping the competitive dynamics of intravenous iron therapies.